Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
Open Access
- 1 December 1993
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 68 (6), 1140-1145
- https://doi.org/10.1038/bjc.1993.494
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activityInternational Journal of Cancer, 1989
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Overexpression of the c‐erbB‐2 protein in human breast tumor cell linesJournal of Cellular Biochemistry, 1989
- A Murine Monoclonal Antibody that Recognizes an Extracellular Domain of the Human c‐erbB‐2 Protooncogene ProductJapanese Journal of Cancer Research, 1989
- erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 CellsScience, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptorNature, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesCell, 1985
- The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenNature, 1984